Pharmaceutical composition comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and potassium ions

A letermovir and potassium ion composition without complexing solubilizers addresses particle formation issues, offering a stable, ready-to-use solution for HCMV treatment with enhanced solubility and stability.

JP2024545465AActive Publication Date: 2024-12-06AIC246 AG & CO KG
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2024537867
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-21
Filing Date
2022-12-21
Publication Date
2024-12-06
Estimated Expiration
2042-12-21

AI Technical Summary

Technical Problem

Existing pharmaceutical compositions containing letermovir, such as those with complexing solubilizing agents like PEG, lysine, arginine, and cyclodextrin, face issues with particle formation and require additional filtration before use, necessitating a stable, particle-free, ready-to-use solution for treating human cytomegalovirus (HCMV) infections.

Method used

A pharmaceutical composition comprising letermovir and potassium ions in a specific molar ratio, free of complexing solubilizers, with a pH range of 7 to 8, which can be lyophilized and redissolved in a parenterally acceptable diluent, ensuring long-term stability and solubility without the need for additional solubilizers.

Benefits of technology

The composition achieves improved solubility and stability, providing a ready-to-use, particle-free solution suitable for intravenous administration, suitable for treating HCMV infections with prolonged stability and effective therapeutic concentrations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545465000001
    Figure 2024545465000001
  • Figure 2024545465000002
    Figure 2024545465000002
  • Figure 2024545465000003
    Figure 2024545465000003
Patent Text Reader

Abstract

The present invention relates to a novel stable pharmaceutical composition comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid and potassium ions, essentially free of complexing solubilizers such as PEG, cyclodextrin, lysine, arginine, in particular HPBCD. The present invention further relates to a method for the preparation of said pharmaceutical composition. The present invention further relates to the use of said pharmaceutical composition in a method for the treatment of a disease and / or as a prophylactic agent, in particular its use as an antiviral agent, preferably against cytomegalovirus.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel stable pharmaceutical composition containing 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid, also known as Letermovir, suitable for oral and intravenous administration and injection, and potassium ions. The pharmaceutical composition is essentially free of certain complexing solubilizing agents, such as PEG, cyclodextrin, lysine, arginine, and especially HPBCD. The formulation is suitable for use in methods for treating viral diseases, particularly human cytomegalovirus (hereinafter HCMV) infections. The present invention also relates to a method for preparing the pharmaceutical composition. [Background technology]

[0002] Cytomegalovirus (CMV) is a common opportunistic infection that causes significant morbidity and preventable mortality after solid organ transplantation and allogeneic hematopoietic stem cell transplantation.

[0003] HCMV is a type of virus that belongs to the family of viruses known as Herpesviridae or herpesviruses. It is typically abbreviated as HCMV and alternatively known as human herpesvirus 5 (HHV-5). Within the Herpesviridae family, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals.

[0004] Letermovir is known as a highly active drug for combating HCMV infection and has been described in detail in Lischka et al., In Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound Letermovir. Antimicrob. Agents Chemother. 2010, 54: p.1290-1297; and Kaul et al., First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound Letermovir. Am. J. Transplant. 2011, 11:1079-1084; and Marschall et al., In Vitro Evaluation of the Activities of the Novel Anticytomegalovirus Compound Letermovir against Herpesviruses and Other Human Pathogenic Viruses. Antimicrob. Agents Chemother. 2012, 56:1135-1137.

[0005] The correct chemical name of letermovir is 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid, and the chemical structure of letermovir is shown below: [ka]

[0006] Letermovir has been developed as an antiviral agent, particularly for the treatment, prevention or prophylaxis of infections caused by human cytomegalovirus (HCMV), and is disclosed in WO 2004 / 096778. Additionally, salts of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid have also been prepared, as described in WO 2013 / 127971.

[0007] A liquid pharmaceutical formulation comprising amorphous letermovir is described in WO 2013 / 127970, which formulation in particular relates to a pharmaceutical composition that can be used for intravenous administration, contains letermovir, has long-term stability, is storable, and has a substantially physiological pH. It has further been discovered that such compositions can be lyophilized to obtain a stable solid pharmaceutical composition that can be redissolved in a simple manner for injection, for example by adding water, resulting in a stable pharmaceutical composition for, for example, intravenous administration.

[0008] However, there remains a need for a pharmaceutical composition comprising letermovir that has long-term stability at substantially physiological pH, suitable for use in subjects of all ages who require solid organ transplantation and allogeneic hematopoietic stem cell transplantation. Moreover, pharmaceutical compositions comprising letermovir and a complexing solubilizer, such as PEG, lysine, arginine, cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD), tend to cause particle problems when dissolved in parenterally acceptable diluents such as water, and therefore require additional workup prior to intended use, such as filtration of the pharmaceutical composition prior to administration. Thus, there remains a need for a ready-to-use, particle-free parenteral solution comprising letermovir. Summary of the Invention

[0009] In a first aspect, the present invention provides a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition is capable of exhibiting a pH in the range of 7 to 8 when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It relates to pharmaceutical compositions.

[0010] At a molar ratio of potassium ion to letermovir of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, and more preferably 0.90-<1.00:1.00, letermovir exhibits improved solubility and is present in sufficient concentrations to achieve the desired therapeutic effect without the need for additional solubilizing agents, particularly complexing solubilizing agents such as cyclodextrins, and pharmaceutical compositions containing potassium ion at said ratios have a substantially physiological pH and exhibit long-term stability.

[0011] It has further been found that the pharmaceutical composition can be obtained in the form of a lyophilisate which can be completely redissolved in parenterally acceptable diluents such as water, aqueous glucose or lactated Ringer's solution. When redissolved, the lyophilisate exhibits a pH in the range of 7-8, preferably 7.4-7.8, when letermovir is present in the reconstituted solution in a concentration range of 1-100 mg / mL, preferably 20-100 mg / mL. The pH of the reconstituted solution is stable in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00 molar ratio of potassium ions to letermovir, which is in the physiological range of 7-8, preferably 7.4-7.8, a clear evidence of the surprising self-buffering action of potassium ions in the given range. The reconstituted solution obtained exhibits long-term stability.

[0012] In another aspect, the present invention provides a method for producing a method for the treatment of a disease comprising the steps of: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80 to <1.00:1.00, preferably 0.88 to <1.00:1.00, more preferably 0.90 to <1.00:1.00; and optionally at least one excipient selected from the group consisting of carbohydrates such as sucrose or mannitol, amino acids such as phenylalanine, polyalkoxy compounds such as poloxamers, particularly poloxamer 188, and polyvinylpyrrolidone (PVP) such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i) to a value in the range of 7-8, preferably using HCl; iii) optionally filtering the solution; The present invention relates to a method for producing the pharmaceutical composition, comprising:

[0013] In particular, the method according to the present invention may further comprise the subsequent steps of lyophilizing the solution obtained in step iii above to obtain a lyophilisate, optionally redissolving the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 1-100 mg / mL, preferably 20-100 mg / mL, with respect to letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, said first and said second parenterally acceptable diluents being the same or different.

[0014] Another aspect of the present invention relates to the use of a pharmaceutical composition as described herein for the preparation of a medicament for the treatment and / or prevention of a disease, in particular a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group.

[0015] Another aspect of the present invention relates to a method for the treatment and / or prevention of a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group, in a subject in need thereof by administering said pharmaceutical composition. In particular, the pharmaceutical composition according to the present invention is suitable for the treatment of newborns, subjects in need of certain solid organ transplants, such as renal compromised subjects and subjects in need of allogeneic hematopoietic stem cell transplantation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] It is noted that the term "comprising" also encompasses the meaning of "consisting of", e.g. a group of members comprising said members also encompasses a group of members consisting only of those members.

[0017] As used herein, the term "room temperature" is synonymous with the term "normal room temperature" and refers to a temperature in the range of 19° C. to 26° C. For example, "stirring at room temperature" means "stirring at a temperature in the range of 19° C. to 26° C.."

[0018] Within the scope of the present invention, the term "stability" is understood to mean not only the chemical stability of the components of the pharmaceutical composition, in particular the active substances, but also the physicochemical stability of the composition itself. In particular, the compositions according to the invention must be stable against precipitation of the constituents.

[0019] In this context, the term "stable" means that the pharmaceutical composition according to the invention contains a minimum of >90%, preferably >95%, more preferably >98% of the active substance during a storage period of at least 1 month, preferably at least 3 months, even more preferably at least 6 months, even more preferably 12 months, even more preferably 18 months and most preferably at least 36 months at 2°C-8°C, or 25°C, or 40°C, as measured according to the HPLC method of the present invention.

[0020] Cyclodextrin according to the invention is understood to include any modified or unmodified cyclodextrin, in particular selected from α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin. Examples of modified β-cyclodextrins include, in particular, hydroxyalkyl-β-cyclodextrins, such as hydroxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin or hydroxypropyl-β-cyclodextrin, alkyl-hydroxyalkyl-β-cyclodextrins, such as methyl-hydroxypropyl-β-cyclodextrin or ethyl-hydroxypropyl-cyclodextrin or sulfoalkyl-cyclodextrin. Hydroxypropyl-β-cyclodextrins are available with different degrees of substitution, in particular 2-hydroxypropyl-β-cyclodextrin, available as Cavasol® W7 HP, Cavitron® W7 HP5 and Cavitron® W7 HP7.

[0021] As used herein, the term "complexing solubilizer" refers to a compound that enhances the solubility of the active ingredient of the pharmaceutical composition of the present invention by forming a coordinate bond between said compound and the molecule of the active ingredient, i.e., by actually and detectably forming a complex with the active ingredient of the pharmaceutical composition of the present invention, especially in aqueous solution.Non-limiting examples of complexing solubilizers include non-polymeric solubilizers such as lysine or arginine, and polymeric solubilizers such as PEG or cyclodextrin.

[0022] As used herein, the terms "parenterally acceptable diluent", "parenteral admixture diluent" and "commercially available diluent" refer to a liquid material used to dilute an active ingredient suitable for administration to a subject by a route other than topical or oral. Examples of parenteral routes include intramuscular, intravascular (including intraarterial or intravenous), intraorbital, retrobulbar, intranasal, subarachnoid, intraventricular, intraspinal, intraperitoneal, intrapulmonary, intracisternal, intraarticular, intrasternal, periocular or intralesional administration. Examples of parenterally acceptable diluents include water, aqueous glucose solution or lactated Ringer's solution. Within this application, the terms "commercially available diluent", "parenteral admixture diluent" and "parenterally acceptable diluent" have the same meaning and are used interchangeably.

[0023] As used herein, the term "carbohydrate" refers to a compound that is a polyhydroxy aldehyde or ketone, or a substance that upon hydrolysis produces such a compound. Some carbohydrates may further contain nitrogen, phosphorus, or sulfur. Examples of carbohydrates include monosaccharides, disaccharides, oligosaccharides, and polysaccharides, particularly sucrose or mannitol.

[0024] As used herein, the term "amino acid" refers to any of the 20 naturally occurring amino acids or their synthetic analogues that have unnatural side chains and include both the D and L optical isomers. Examples of amino acids include alanine and phenylalanine, among others.

[0025] As used herein, the term "polyalkoxy compound" refers to a polymeric compound in which repeating units represent an alkyl group having a straight or branched chain linked to an oxygen atom. Examples of polyalkoxy compounds include poloxamers, particularly poloxamer 188.

[0026] Within the scope of the present invention, the terms "obtained by" and "obtainable by" have the same meaning and are used interchangeably.

[0027] Within the scope of the present invention, the term "equivalent" is understood to mean "molar equivalent".

[0028] As used herein, the term "aqueous solution" refers to a liquid homogeneous mixture that contains water.

[0029] As used herein, the terms "lyophilization and freeze-drying" are used interchangeably and refer to a process in which a desired product containing a solvent, particularly water, is cooled, particularly by using liquid nitrogen or a cooling shelf, to a sufficient temperature in which some or all of the solvent is frozen, and the frozen solvent is further removed by one or more drying steps, particularly by removal of unbound solvent by sublimation and desorption. The terms "lyophilisate" and "lyophilized product" refer to the product obtained by lyophilization and are used interchangeably throughout this specification.

[0030] As used herein, the terms "reconstitution" or "reconstituting" refer to the process of dissolving the lyophilisate in a diluent, preferably a parenterally acceptable diluent, especially water. A "reconstituted solution" refers to the product obtained by reconstitution.

[0031] As used herein, the term "treatment" or "treating" is defined as the application or administration of a therapeutic agent, i.e., letermovir (alone or in combination with another agent), to a subject, or to an isolated tissue or cell line derived from a subject having an HCMV infection, a symptom of an HCMV infection, or the potential for developing an HCMV infection, with the intent to cure, heal, reduce, ameliorate, alter, treat, ameliorate, or affect the HCMV infection, the symptoms of an HCMV infection, or the potential for developing an HCMV infection. Such treatments can be specifically tailored or modified based on knowledge gained from the field of pharmacogenomics.

[0032] As used herein, the terms "prevent", "preventing" or "prevention" refer to the absence of onset of a disorder or disease in cases where there has been no onset of the disorder or disease, or the absence of further progression of the disorder or disease in cases where there has already been onset of the disorder or disease. Also considered is the ability to prevent some or all of the symptoms associated with a disease or disease. Prevention of a disease encompasses prophylaxis of a disease.

[0033] As used herein, the term "subject" refers to a human or non-human mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, feline, canine, and murine mammals. Preferably, the subject is a human. In one embodiment, the subject is a human infant. In a preferred embodiment, the subject is a human newborn. In another preferred embodiment, the subject is a subject in need of a particular solid organ transplant, such as a subject with renal impairment and a subject in need of an allogeneic hematopoietic stem cell transplant.

[0034] As used herein, the term "pharmaceutically acceptable" refers to a material, such as a carrier or diluent, that does not destroy the biological activity or properties of the compound and is relatively non-toxic, i.e., the material may be administered to a subject without causing undesired biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0035] As used herein, the term "essentially free" refers to a content of less than 5 mole percent.

[0036] The subject of the present invention is a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL, of letermovir, can exhibit a pH range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It relates to pharmaceutical compositions.

[0037] The subject of the present invention is also a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.80-0.90:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It relates to pharmaceutical compositions.

[0038] The subject of the present invention is also a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 1 to 100 mg / mL, preferably 20 to 100 mg / mL, of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD), It relates to pharmaceutical compositions.

[0039] In one embodiment, the potassium ions in the pharmaceutical composition are contained in the form of a solution of potassium hydroxide (KOH), preferably an aqueous solution of KOH.

[0040] In one embodiment, the pharmaceutical composition according to the invention is essentially free of compounds selected from the group consisting of PEG, lysine, arginine, and cyclodextrin. In one embodiment, the pharmaceutical composition according to the invention is essentially free of lysine. In another embodiment, the pharmaceutical composition according to the invention is essentially free of arginine. In yet another embodiment, the pharmaceutical composition according to the invention is essentially free of PEG. In yet another embodiment, the pharmaceutical composition according to the invention is essentially free of cyclodextrin. In a preferred embodiment, the pharmaceutical composition according to the invention is essentially free of hydroxypropyl-β-cyclodextrin. In another preferred embodiment, the pharmaceutical composition according to the invention is essentially free of PEG, lysine, arginine, and cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD).

[0041] In one embodiment, the pharmaceutical composition according to the invention is essentially free of complexing solubilizers, in particular essentially free of PEG, lysine, arginine, and cyclodextrins, in particular hydroxypropyl-β-cyclodextrin (HPBCD).

[0042] In one embodiment, the content of complexing solubilizer in the pharmaceutical composition according to the invention is less than 5 mol%. In a preferred embodiment, the content of complexing solubilizer in the pharmaceutical composition according to the invention is less than 3 mol%. In a more preferred embodiment, the content of complexing solubilizer in the pharmaceutical composition according to the invention is less than 1 mol%. In a more preferred embodiment, the content of complexing solubilizer in the pharmaceutical composition according to the invention is less than 0.5 mol%. Most preferably, the content of complexing solubilizer in the pharmaceutical composition according to the invention is less than 0.3 mol%.

[0043] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0044] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.84 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0045] In a preferred embodiment, a pharmaceutical composition according to the present invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.88 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0046] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.90 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0047] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0048] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.84 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0049] In a preferred embodiment, a pharmaceutical composition according to the present invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.88 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0050] In a more preferred embodiment, the pharmaceutical composition according to the present invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.90 to <1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0051] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0052] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.84 to <1.00:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0053] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.88 to <1.00:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0054] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.90 to <1.00:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% w / v glucose solution in water, in a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7-8, preferably 7.4-7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0055] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.80 to <1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and It is essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, particularly hydroxypropyl-β-cyclodextrin (HPBCD).

[0056] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.84 to <1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0057] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.88 to <1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0058] In one embodiment, a pharmaceutical composition according to the invention comprises letermovir and potassium ions, wherein said pharmaceutical composition comprises: potassium ions in a molar ratio relative to letermovir in the range of 0.90 to <1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 20 to 100 mg / mL of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and · Essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, and cyclodextrin, especially hydroxypropyl-β-cyclodextrin (HPBCD).

[0059] In one embodiment, the pharmaceutical composition according to the present invention contains potassium ion in a molar ratio to letermovir in the range of 0.80 to <1.00:1.00, preferably 0.81 to <1.00:1.00, more preferably 0.82 to <1.00:1.00, more preferably 0.83 to <1.00:1.00, more preferably 0.84 to <1.00:1.00, more preferably 0.85 to <1.00:1.00, more preferably 0.86 to <1.00:1.00, more preferably 0.87 to <1.00:1.00, more preferably 0.88 to <1.00:1.00, more preferably 0.89 to <1.00:1.00, and more preferably 0.90 to <1.00:1.00.

[0060] In one embodiment, the pharmaceutical composition according to the invention comprises potassium ions in the form of potassium hydroxide solution (KOH), preferably an aqueous solution of KOH, in a molar ratio to letermovir in the range of 0.80 to <1.00:1.00, preferably 0.81 to <1.00:1.00, more preferably 0.82 to <1.00:1.00, more preferably 0.83 to <1.00:1.00, more preferably 0.84 to <1.00:1.00, more preferably 0.85 to <1.00:1.00, more preferably 0.86 to <1.00:1.00, more preferably 0.87 to <1.00:1.00, more preferably 0.88 to <1.00:1.00, more preferably 0.89 to <1.00:1.00, more preferably 0.90 to <1.00:1.00.

[0061] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in water at a concentration range of 20 to 100 mg / mL with respect to letermovir.

[0062] In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when the pharmaceutical composition is dissolved in water to a concentration range of 1 to 100 mg / mL of letermovir. In a more preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when the pharmaceutical composition is dissolved in water to a concentration range of 20 to 100 mg / mL of letermovir.

[0063] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when said pharmaceutical composition is dissolved in an aqueous glucose solution, preferably a 5% (wt / vol) glucose solution in water, in a concentration range of 20 to 100 mg / mL with respect to letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when said pharmaceutical composition is dissolved in an aqueous glucose solution, preferably a 5% (wt / vol) glucose solution in water, in a concentration range of 20 to 100 mg / mL with respect to letermovir.

[0064] In one embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7 to 8 when the pharmaceutical composition is dissolved in lactated Ringer's solution at a concentration range of 20 to 100 mg / mL of letermovir. In a preferred embodiment, the pharmaceutical composition according to the present invention can exhibit a pH in the range of 7.4 to 7.8 when the pharmaceutical composition is dissolved in lactated Ringer's solution at a concentration range of 20 to 100 mg / mL of letermovir.

[0065] In one embodiment, there is provided a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition, when dissolved in water at a concentration range of 1 to 100 mg / mL with respect to letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD); Further comprising at least one pharmaceutical carrier or excipient; Pharmaceutical compositions.

[0066] In one embodiment, there is provided a pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition, when dissolved in an aqueous glucose solution, preferably a 5% (weight / volume) glucose solution in water, in a concentration range of 1 to 100 mg / mL, preferably 20 to 100 mg / mL with respect to letermovir, is capable of exhibiting a pH in the range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD); Further comprising at least one pharmaceutical carrier or excipient; Pharmaceutical compositions.

[0067] In one embodiment, the pharmaceutical composition comprises letermovir of formula (I) and potassium ions, [ka] potassium ions in a molar ratio relative to letermovir in the range of 0.80-<1.00:1.00, more preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and the pharmaceutical composition, when dissolved in lactated Ringer's solution at a concentration of 1 to 100 mg / mL, preferably 20 to 100 mg / mL, of letermovir, can exhibit a pH in the range of 7 to 8, preferably 7.4 to 7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD); Further comprising at least one pharmaceutical carrier or excipient; Pharmaceutical compositions.

[0068] In one embodiment, the pharmaceutical composition according to the invention comprises at least one excipient selected from the group consisting of carbohydrates such as sucrose or mannitol, amino acids such as phenylalanine, polyalkoxy compounds such as poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP) such as PVP PF12. In a preferred embodiment, said excipient is mannitol or sucrose or a combination thereof.

[0069] In one embodiment, the pharmaceutical composition according to the invention is essentially free of complexing solubilizers.

[0070] In one embodiment, the pharmaceutical composition according to the present invention can contain an excipient that exhibits complexing solubilizing properties. In one embodiment, such an excipient is a polyalkoxy compound such as a poloxamer. In one embodiment, the poloxamer is poloxamer 188.

[0071] In one embodiment, a pharmaceutical composition according to the invention comprises a polyalkoxy compound, such as a poloxamer, such as Poloxamer 188, and is essentially free of other complexing solubilizers.

[0072] In one embodiment, the excipients used are suitable for administration to subjects in need of certain solid organ transplants, such as subjects with impaired kidneys and subjects in need of allogeneic hematopoietic stem cell transplants. Non-limiting examples of such excipients include sucrose, mannitol, phenylalanine, and poloxamers, such as poloxamer 188, and polyvinylpyrrolidone (PVP), such as PVP PF12.

[0073] In one embodiment, the pharmaceutical composition according to the invention further comprises a buffer, preferably trishydroxyaminomethane (Tris).

[0074] In one embodiment, the pharmaceutical composition according to the invention further comprises HCl.

[0075] In one embodiment, the pharmaceutical composition according to the invention exhibits stability according to ICH Q1A(R2) (Stability testing of new drug substances and formulations) covering climatic zones I-IV. In a preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 1 month. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 3 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 6 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 12 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 18 months. In a more preferred embodiment, the pharmaceutical composition according to the invention is stable for at least 36 months.

[0076] In one embodiment, the pharmaceutical composition according to the invention is in solid form. In a preferred embodiment, said solid form of said pharmaceutical composition is a lyophilisate.

[0077] In one embodiment, the pharmaceutical composition according to the invention is in liquid form. In a preferred embodiment, said liquid form of the pharmaceutical composition according to the invention is an aqueous solution. In another preferred embodiment, said liquid form of the pharmaceutical composition according to the invention is a solution in at least one parenterally acceptable diluent. Non-limiting examples of parenterally acceptable diluents include water, aqueous glucose solution and lactated Ringer's solution.

[0078] In one embodiment, a pharmaceutical composition according to the invention is suitable for intravenous (IV) administration or injection.

[0079] The subject matter of the present invention further comprises the steps of: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80-<1.00:1.00, preferably 0.84-<1.00:1.00, more preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, in particular sucrose or mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12; The present invention also relates to a method for producing a pharmaceutical composition according to the present invention, comprising:

[0080] In one embodiment, the solution obtained in step i above is a solution in a parenterally acceptable diluent such as water.

[0081] In one embodiment, potassium ions are provided in step i in the form of a KOH solution, preferably an aqueous KOH solution.

[0082] In one embodiment, providing the solution according to step i above comprises the steps of: a-1) preparing a suspension of letermovir in a parenterally acceptable diluent, in particular water; b-1) adding KOH to the suspension obtained in step a-1 to obtain a mixture; c-1) optionally stirring the mixture obtained in step b-1 for at least 30 minutes; d-1) optionally adding to said mixture at least one excipient selected from the group consisting of carbohydrates, particularly sucrose and mannitol, amino acids, particularly phenylalanine, polyalkoxy compounds, particularly poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), particularly PVP PF12; e-1) optionally stirring the mixture for at least 30 minutes; Includes.

[0083] In a preferred embodiment, an aqueous solution of KOH is added in step b-1.

[0084] In a preferred embodiment, the solution in step c-1 is stirred for at least 2 hours.

[0085] In a preferred embodiment, the solution in step e-1 is stirred for at least 2 hours.

[0086] In a preferred embodiment, 0.80 to <1.00 equivalents of KOH relative to letermovir are added in step b-1. In a more preferred embodiment, 0.84 to <1.00 equivalents of KOH relative to letermovir are added in step b-1. In a more preferred embodiment, 0.88 to <1.00 equivalents of KOH relative to letermovir are added in step b-1. In a more preferred embodiment, 0.90 to <1.00 equivalents of KOH relative to letermovir are added in step b-1.

[0087] In one embodiment, 0.80 equivalents of KOH relative to letermovir are added in step b-1. In one embodiment, 0.82 equivalents of KOH relative to letermovir are added in step b-1. In one embodiment, 0.84 equivalents of KOH relative to letermovir are added in step b-1. In one embodiment, 0.86 equivalents of KOH relative to letermovir are added in step b-1. In one embodiment, 0.88 equivalents of KOH relative to letermovir are added in step b-1. In one embodiment, 0.90 equivalents of KOH relative to letermovir are added in step b-1.

[0088] In another embodiment, the method for preparing a solution according to step i includes, instead of steps a-1 to e-1, the following steps a-2 to e-2: a-2) preparing a solution of KOH in a parenterally acceptable diluent, especially water; b-2) adding letermovir to the solution obtained in step a-2 to obtain a mixture; c-2) optionally stirring the mixture obtained in step b-2 for at least 30 minutes; d-2) optionally adding to said mixture at least one excipient selected from the group consisting of carbohydrates, in particular sucrose and mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12; e-2) optionally stirring the mixture for at least 30 minutes; This includes the use of.

[0089] In a preferred embodiment, the solution in step c-2 is stirred for at least 2 hours.

[0090] In a preferred embodiment, the solution in step e-2 is stirred for at least 2 hours.

[0091] In a preferred embodiment, 1.25 to >1.00 equivalents of letermovil relative to KOH are added in step b-2. In a more preferred embodiment, 1.19 to >1.00 equivalents of letermovil relative to KOH are added in step b-2. In a more preferred embodiment, 1.14 to >1.00 equivalents of letermovil relative to KOH are added in step b-2. In a more preferred embodiment, 1.11 to >1.00 equivalents of letermovil relative to KOH are added in step b-2.

[0092] In one embodiment, 1.25 equivalents of letermovil relative to KOH are added in step b-2. In one embodiment, 1.22 equivalents of letermovil relative to KOH are added in step b-2. In one embodiment, 1.19 equivalents of letermovil relative to KOH are added in step b-2. In one embodiment, 1.16 equivalents of letermovil relative to KOH are added in step b-2. In one embodiment, 1.14 equivalents of letermovil relative to KOH are added in step b-2. In one embodiment, 1.11 equivalents of letermovil relative to KOH are added in step b-2.

[0093] In one embodiment, the method for producing a pharmaceutical composition according to the present invention further comprises adjusting the pH of the solution obtained in step i to a range of 7-8, preferably 7.4-7.8. In one preferred embodiment, said adjustment is performed by adding HCl. In a more preferred embodiment, the pH of the solution obtained in step i is in the range of 7-8, preferably 7.4-7.8, and no pH adjustment is required.

[0094] In one embodiment, the solution obtained after pH adjustment is optionally stirred for at least 10 minutes, preferably at least 30 minutes.

[0095] In one embodiment, the method for producing a pharmaceutical composition according to the invention optionally comprises filtering the solution obtained in step i. In one embodiment, the method for producing a pharmaceutical composition according to the invention optionally comprises filtering the solution obtained after adjusting the pH of the solution obtained in step i above.

[0096] In one embodiment, the method for producing a pharmaceutical composition according to the present invention further comprises lyophilizing the resulting solution to obtain a lyophilisate.

[0097] In one embodiment, the method for preparing the pharmaceutical composition according to the present invention further comprises reconstituting the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 0.1-100 mg / mL with respect to letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion. The first and second parenterally acceptable diluents may be the same or different. In one embodiment, when letermovir is present in the reconstituted solution in the concentration range of 0.1-100 mg / mL, said reconstituted solution exhibits a pH in the range of 7-8, preferably 7.4-7.8. In a preferred embodiment, when letermovir is present in the reconstituted solution in the concentration range of 20-100 mg / mL, said reconstituted solution exhibits a pH in the range of 7-8, preferably 7.4-7.8.

[0098] In one embodiment, the final concentration acceptable for injection or injection is in the range of 0.1 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 0.8 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 20 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 50 to 100 mg / mL. In another embodiment, the final concentration acceptable for injection or injection is in the range of 20 to 50 mg / mL. In a preferred embodiment, the final concentration acceptable for injection or injection is 0.8 mg / mL.

[0099] In a preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80-<1.00:1.00, preferably 0.84-<1.00:1.00, more preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and optionally at least one excipient selected from the group consisting of a carbohydrate, such as sucrose or mannitol; an amino acid, such as phenylalanine; a polyalkoxy compound, such as a poloxamer, in particular poloxamer 188; and a polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7-8, preferably 7.4-7.8, using suitable organic and inorganic acids; iii) optionally filtering the resulting solution; Includes.

[0100] In one embodiment of step ii, the organic or inorganic acid is HCl.

[0101] In another preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80-<1.00:1.00, preferably 0.84-<1.00:1.00, more preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and optionally at least one excipient selected from the group consisting of a carbohydrate, such as sucrose or mannitol; an amino acid, such as phenylalanine; a polyalkoxy compound, such as a poloxamer, in particular poloxamer 188; and a polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7-8, preferably 7.4-7.8, using suitable organic and inorganic acids; iii) optionally filtering the resulting solution; iv) freeze-drying the resulting solution to obtain a lyophilisate; Includes.

[0102] In one embodiment of step ii, the organic or inorganic acid is HCl.

[0103] In another preferred embodiment, the method for producing a pharmaceutical composition according to the present invention comprises the following steps: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80-<1.00:1.00, preferably 0.84-<1.00:1.00, more preferably 0.88-<1.00:1.00, more preferably 0.90-<1.00:1.00; and optionally at least one excipient selected from the group consisting of a carbohydrate, such as sucrose or mannitol; an amino acid, such as phenylalanine; a polyalkoxy compound, such as a poloxamer, in particular poloxamer 188; and a polyvinylpyrrolidone (PVP), such as PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i to a value in the range of 7-8, preferably 7.4-7.8, using suitable organic and inorganic acids; iii) optionally filtering the resulting solution; iv) freeze-drying the resulting solution to obtain a lyophilisate; v) reconstituting the lyophilisate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 1-100 mg / mL, preferably 20-100 mg / mL, with respect to letermovir, and optionally further diluting said reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, wherein said first and said second parenterally acceptable diluents can be the same or different; Includes.

[0104] In one embodiment of step ii, the organic or inorganic acid is HCl.

[0105] The above steps i-v do not necessarily imply a particular order or number of steps. However, preferably, the steps of the method of the present invention are performed in the above order. Some of the steps may be optional, and in some embodiments, optional steps are not performed. For example, in one embodiment, step ii may be immediately followed by step iv without performing step iii. Also, the steps shown above do not exclude additional steps not explicitly mentioned. For example, the solution obtained in step i and / or ii may be optionally stirred.

[0106] The subject of the present invention further relates to a pharmaceutical composition obtainable by any of the methods disclosed herein.

[0107] The pharmaceutical composition according to the invention can be used for the manufacture of a medicament suitable for use in a method for the prevention and / or treatment of infections caused by representatives of the Herpesviridae group, in particular cytomegalovirus, in particular human cytomegalovirus.

[0108] Furthermore, a subject of the present invention relates to a pharmaceutical composition according to the invention for use in a method for the treatment and / or prevention of a disease, preferably a viral infection, in particular an infection caused by human cytomegalovirus (HCMV) or other representatives of the Herpesviridae group.

[0109] A further aspect of the present invention relates to the use of a pharmaceutical composition according to the invention in a method for the treatment and / or prevention of diseases, preferably viral infections, in particular infections caused by human cytomegalovirus (HCMV) or other representatives of the Herpesviridae group.

[0110] Another aspect of the present invention relates to the use of a pharmaceutical composition according to the present invention for the preparation of a medicament for the treatment and / or prevention of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group.

[0111] Yet another aspect of the present invention relates to a method for treating and / or preventing a viral infection, preferably a human cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group, in a subject in need thereof by administering a pharmaceutical composition according to the present invention, hi one embodiment, said subject is selected from the group consisting of newborns, subjects in need of a particular solid organ transplant, e.g. subjects with impaired kidneys and subjects in need of an allogeneic hematopoietic stem cell transplant.

[0112] In general, it has proven advantageous to administer the pharmaceutical composition in such a way that about 0.001 to 10 mg of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid (letermovir) is administered per kg of body weight, preferably 0.01 to 5 mg per kg.

[0113] Nevertheless, it may be necessary to deviate from the aforementioned amount of letermovir, depending, inter alia, on body weight, individual response to the active substance, and the time and interval at which it is administered.For example, in certain cases, it may be sufficient to administer less than the aforementioned minimum amount of letermovir, while in other cases the upper limit described may be exceeded.When administering larger amounts, it may be advisable to divide them into several individual doses per day.

[0114] The present invention will now be described in detail with reference to non-limiting examples.

[0115] Unless otherwise stated, the percentages given in the following tests and examples are percentages by weight, the parts are parts by weight and the solvent ratios, dilution ratios and concentrations of liquid solutions are in each case related to volume.

[0116] Abbreviation API Active Pharmaceutical Ingredients h hour(s) HCl Hydrochloric acid HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) HPBCD Hydroxypropyl-β-cyclodextrin HPLC High Pressure Liquid Chromatography conc. concentration min. LAF laminar flow PEG Polyethylene glycol PDE daily exposure allowance RT (HPLC) retention time RP-HPLC Reversed Phase High Pressure Liquid Chromatography rpm revolutions per minute rt room temperature

[0117] Analysis method Visual inspection Samples were gently manually radially agitated in front of a white background for 5 seconds and inspected for the presence of visible particles.

[0118] pH The pH values ​​of the samples were measured using a calibrated pH meter EUTEGH CAKTON PH / Ion 510 serial number 172361 with a Polilyte lab electrode. The sample was stirred and the electrode was introduced. Measurements were taken until the pH value stabilized. The electrode was thoroughly rinsed with water between measurements. pH measurements were performed with an analytical volume of ~1-2 mL and at a specified temperature of 22°C ± 3°C. A three-point correction of the pH meter was performed daily using buffers of pH 7.00, pH 4.01 and pH 10.01 (Hamilton Duracal buffer).

[0119] Reversed-phase high-performance liquid chromatography (RP-HPLC) RP-HPLC was used to measure the concentrations of letermovir free base and possible degradation products.

[0120] Table 1 shows an overview of the eluents used in the RP-HPLC analysis. Table 1: Eluents used for RP-HPLC analysis [Table 1]

[0121] The following parameters were used for the RP-HPLC method: Instrumentation: Agilent Technologies 1200 Series with VWD G131413 detector Column: Agilent Zorbax Eclipse XDB C-18, 150×4.6mm, 5μm Flow rate: 1.0ml / min Solvent A: 0.1% formic acid in water Solvent B: 0.1% formic acid in 100% methanol End time: 26 minutes Injection volume: 10μl Column temperature: 35℃ Wavelength: 260nm

[0122] The gradient used for the RP-HPLC method is shown in Table 2. Table 2: Gradient applied during RP-HPLC analysis [Table 2]

[0123] A calibration curve of the reference standard was used to quantitate letermovir free base in solution.

[0124] Samples were diluted to approximately 2 mg / mL in water (corrected for letermovir free base in solution) and analyzed with an injection volume of 10 μl. Prior to injection, diluted samples were filtered through a syringe filter (nylon, 0.45 μm).

[0125] Peak integration was performed manually for all API related peaks. Peaks that were also present in the blank or formulation buffer injections were ignored.

[0126] Powder X-ray Diffraction (PXRD) Equipment: Powder diffraction patterns were acquired in transmission geometry on a Bruker D8 Advance Series 2 Theta / Theta powder diffraction system using CuKα1 radiation. The system was equipped with a VÅNTEC-1 single photon counting PSD, a germanium monochromator, a fixed divergence slit and a radial solar. Software used: Data acquisition with DIFFRAC and XRD Commander V.2.5.1 and evaluation with EVA V.5.0.0.22 (Bruker-AXS 2010-2018).

[0127] Sample preparation: Approximately 15 mg of raw sample was prepared in a standard sample holder using two foils of polyacetate.

[0128] Measurement conditions: Samples were measured in the 2θ range of 4° to 40° at room temperature for a 0.1 hour measurement with an angle step of 0.049° and a time per step of 2787 seconds. EXAMPLES

[0129] Example 1. Observation of solutions of Letermovir free base with different equivalent amounts of potassium hydroxide at different temperatures. a) Initial drying Twenty-six samples of letermovir free base were prepared by weighing the material and drying overnight at 90°C (approximately 5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of KOH was calculated (Table 3). Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions.

[0130] Table 3. Primary drying process of 26 samples of letermovir free base. [Table 3]

[0131] b) Preparation of suspensions / solutions and analysis of pH and solubility Procedure: The corresponding amount of water and the respective equivalent amount of 1M KOH aqueous solution were added to each sample. The suspensions were stirred at room temperature, 40°C or 60°C, respectively. The pH, solubility and precipitation were observed after 12 hours, 24 hours, 48 ​​hours and 7 days (Table 4, Table 5, Table 6 and Table 7).

[0132] Table 4. Preparation of samples of letermovir free base at 20 mg / mL in water with different equivalent amounts of KOH at room temperature. [Table 4]

[0133] Table 5. Preparation of Letermovir free base samples at 100 mg / mL in water with different equivalent amounts of KOH at room temperature. [Table 5]

[0134] Table 6. Preparation of samples of letermovir free base at 20 mg / mL in water with different equivalent amounts of KOH at 40°C and 60°C. [Table 6]

[0135] Table 7. Preparation of samples of letermovir free base at 100 mg / mL in water with different equivalent amounts of KOH at 40°C and 60°C. [Table 7]

[0136] result In the samples with 20 mg / mL letermovir free base and KOH, particles are always present in suspension except for the sample with 1 equivalent of KOH, where only a few particles remain in solution, in the air-water phase. All samples of 100 mg / mL letermovir free base and KOH were completely dissolved (only a few particles remained in solution and in the air-water phase for the first two days). Increasing the temperature has slightly different effects: 40℃ - Samples of 20 mg / mL letermovir free base with 0.84, 0.86 and 0.88 equivalents of KOH have particles in suspension and are cloudy in appearance. - Samples of 100 mg / mL letermovir free base with 0.84, 0.86 and 0.88 equivalents of KOH have particles present in the suspension. 60℃ - In the sample with 20 mg / mL letermovir free base and 0.84 equivalents of KOH, there are particles in the suspension. - The samples of 20 mg / mL letermovir free base with 0.86 and 0.88 equivalents of KOH and the samples of 100 mg / mL letermovir free base with 0.84, 0.86 and 0.88 equivalents of KOH were clear solutions from the first day through one week.

[0137] Example 2. Lyophilization after 7 days and reconstitution with water a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material and drying overnight at 90° C. (approximately 5 mbar) in a vacuum oven to remove residual water and avoid weighing errors, and the equivalent amount of KOH was calculated (Table 15). Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions.

[0138] Table 8. Primary drying process of 14 samples of letermovir free base [Table 8]

[0139] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent amount of 1M KOH in water were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 9).

[0140] Table 9. Preparation of Letermovir free base samples with different equivalents of KOH in water. [Table 9]

[0141] Solubility over 7 days After one week, a precipitate remains in the 20 mg / mL and 0.8, 0.82, 0.84, and 0.86 equivalents of KOH samples. A small amount of solids is observed in the 20 mg / mL and 0.88 equivalents of KOH sample, and the 20 mg / mL and 0.9 and 1 equivalents of KOH samples are clear solutions. All 100 mg / mL samples are clear solutions after one week.

[0142] The remaining samples were clear solutions after one week as determined by visual inspection.

[0143] c) Lyophilization and reconstitution with water After one week, the samples were freeze-dried.

[0144] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 3 mL of water and the precipitation and pH were checked (Table 8).

[0145] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 100 mg / mL, the resulting solid was dissolved with about 13 mL of water and the precipitation and pH were checked (Table 10).

[0146] Table 10. Lyophilization and reconstitution in water [Table 10]

[0147] The behavior of the samples with initial and final concentrations of 20 mg / mL is the same before and after lyophilization and reconstitution with water. However, the solubility of the samples with initial concentrations of 100 mg / mL is low when reconstituted with water at a concentration of 20 mg / mL. Only the samples with larger amounts of KOH are completely soluble.

[0148] Example 3. Freeze-drying after 7 days and reconstitution with lactated Ringer's solution a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material, removing residual water, and drying overnight in a vacuum oven at 90° C. (approximately 5 mbar) to avoid weighing errors, and the equivalent amount of KOH was calculated (Table 11). Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions.

[0149] Table 11. Primary drying process of 14 samples of letermovir free base [Table 11]

[0150] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent amount of 1M KOH in water were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 19).

[0151] Table 12. Preparation of Letermovir free base samples with different equivalents of KOH in water. [Table 12]

[0152] Solubility over 7 days After one week, a precipitate remains in the 20 mg / mL and 0.8, 0.82, 0.84, and 0.86 equivalents of KOH samples. A small amount of solids is observed in the 20 mg / mL and 0.88 equivalents of KOH sample, and the 20 mg / mL and 0.9 and 1 equivalents of KOH samples are clear solutions. All 100 mg / mL samples are clear solutions after one week.

[0153] c) Lyophilization and reconstitution with lactated Ringer's solution After one week, the samples were freeze-dried.

[0154] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved with about 3 mL of lactated Ringer's solution and the precipitation and pH were checked (Table 13).

[0155] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 100 mg / mL, the resulting solid was dissolved with about 13 mL of lactated Ringer's solution and the precipitation and pH were checked (Table 13).

[0156] Table 13. Lyophilization and reconstitution with lactated Ringer's [Table 13]

[0157] For samples with a concentration of 20 mg / mL, the behavior before and after lyophilization and reconstitution with lactated Ringer's solution is slightly different: while the sample with the lower amount of KOH was not completely dissolved before lyophilization, upon reconstitution everything dissolved and a clear solution was obtained.

[0158] Example 4. Lyophilization after 7 days and reconstitution with 5% aqueous glucose solution a) Initial drying Fourteen samples of letermovir free base were prepared by weighing the material, removing residual water, and drying overnight in a vacuum oven at 90° C. (approximately 5 mbar) to avoid weighing errors, and the equivalent amount of KOH was calculated (Table 14). Approximately 80 mg and 300 mg of sample were weighed out and dissolved in 4 mL and 3 mL, respectively, to prepare 20 mg / mL and 100 mg / mL solutions.

[0159] Table 14. Primary drying process of 14 samples of letermovir free base [Table 14]

[0160] b) Preparation of suspensions / solutions and analysis of solubility Procedure: A corresponding amount of water and the respective equivalent amount of 1M KOH aqueous solution were added to each sample. The suspensions were stirred at room temperature and the effect on solubility and precipitation was examined (Table 15).

[0161] Table 15. Preparation of Letermovir free base samples with different equivalents of KOH in water. [Table 15]

[0162] Solubility over 7 days After one week, a precipitate remains in the 20 mg / mL and 0.8, 0.82, 0.84, and 0.86 equivalents of KOH samples. A small amount of solids is observed in the 20 mg / mL and 0.88 equivalents of KOH sample, and the 20 mg / mL and 0.9 and 1 equivalents of KOH samples are clear solutions. All 100 mg / mL samples are clear solutions after one week.

[0163] c) Lyophilization and reconstitution with 5% glucose in water After one week, the samples were freeze-dried.

[0164] procedure: 20 mg / mL sample: 3 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 20 mg / mL, the resulting solid was dissolved using about 3 mL of 5% glucose solution and the precipitation and pH were checked (Table 16).

[0165] 100 mg / mL sample: 2.6 mL aliquots were placed in a freezer for 2 hours. The samples were frozen using liquid nitrogen and the lyophilization process was carried out over a period of 2 days (average vacuum about 0.05 mbar, temperature about -86°C). A white amorphous powder was obtained. The resulting solid was analyzed by PXRD, which confirmed the amorphous nature of the lyophilized material. To obtain a final concentration of 100 mg / mL, the resulting solid was dissolved using about 13 mL of 5% glucose solution and the precipitation and pH were checked (Table 16).

[0166] Table 16. Lyophilization and reconstitution with 5% glucose in water [Table 16]

[0167] Reconstitution with 5% glucose solution has similar results to reconstitution with water. Only samples containing larger amounts of KOH are completely dissolved.

Claims

1. A pharmaceutical composition comprising letermovir of formula (I) and potassium ions, [Case 1] said potassium ions in a molar ratio relative to letermovir ranging from 0.80 to <1.00:1.00, preferably from 0.88 to <1.00:1.00, more preferably from 0.90 to <1.00:1.00; and The pharmaceutical composition, when dissolved in water at a concentration range of 20-100 mg / mL with respect to letermovir, is capable of exhibiting a pH range of 7-8, preferably 7.4-7.8; and essentially free of complexing solubilizers selected from the group consisting of PEG, lysine, arginine, cyclodextrin, in particular hydroxypropyl-β-cyclodextrin (HPBCD); Pharmaceutical compositions.

2. 2. The pharmaceutical composition according to claim 1, wherein the potassium ions are contained in the form of a solution of potassium hydroxide (KOH), preferably an aqueous solution of KOH.

3. 3. The pharmaceutical composition according to claim 1 or 2, further comprising at least one excipient selected from the group consisting of carbohydrates, in particular selected from sucrose and mannitol, amino acids, in particular phenylalanine, polyalkoxy compounds, in particular poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), in particular PVP PF12.

4. 3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition is essentially free of complexing solubilizers.

5. 4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition comprises a polyalkoxy compound, in particular a poloxamer, more particularly poloxamer 188, and is essentially free of other complexing solubilizers.

6. 4. The pharmaceutical composition of claim 3, wherein the excipient is mannitol or sucrose or a combination thereof.

7. The pharmaceutical composition according to any one of claims 1 to 6, further comprising a buffer, preferably trishydroxyaminomethane (Tris).

8. A method for producing a pharmaceutical composition according to any one of claims 1 to 7, comprising the steps of: i) providing a solution of letermovir and potassium ions, the molar ratio of potassium ions to letermovir being in the range of 0.80 to <1.00:1.00, preferably 0.88 to <1.00:1.00, more preferably 0.90 to <1.00:1.00, and optionally at least one excipient selected from the group consisting of carbohydrates, particularly sucrose or mannitol, amino acids, particularly phenylalanine, polyalkoxy compounds, particularly poloxamers, more particularly poloxamer 188, and polyvinylpyrrolidone (PVP), particularly PVP PF12; ii) if necessary, adjusting the pH of the solution obtained in step i) to a value in the range of 7-8, preferably 7.4-7.8, preferably with HCl; iii) optionally filtering the solution; A method comprising:

9. 9. The method according to claim 8, wherein the potassium ions are provided in step i in the form of a KOH solution, preferably an aqueous KOH solution.

10. 10. The method of claim 9, further comprising a subsequent additional step of lyophilizing the resulting solution to obtain a lyophilisate.

11. 11. The method of claim 10, further comprising a subsequent additional step of reconstituting the lyophilizate in a first parenterally acceptable diluent to obtain a reconstituted solution in the concentration range of 20 to 100 mg / mL with respect to letermovir, followed by diluting the reconstituted solution with a second parenterally acceptable diluent to a final concentration acceptable for injection or infusion, wherein the first and second parenterally acceptable diluents can be the same or different.

12. A pharmaceutical composition according to any one of claims 1 to 7 for use in a method for the treatment and / or prevention of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection by another member of the Herpesviridae group.

13. Use of a pharmaceutical composition according to any one of claims 1 to 7 for the preparation of a medicinal product for the treatment and / or prevention of a disease, in particular a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection with another member of the Herpesviridae group.

14. A method for the treatment and / or prevention of a viral infection, preferably a Human Cytomegalovirus (HCMV) infection or an infection due to another member of the Herpesviridae group, in a subject in need thereof, comprising administering a pharmaceutical composition according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Pharmaceutical composition containing letermovir

    CN109966244A

  • Antiviral substituted dihydroquinazolines

    JP2006525249A

  • Pharmaceutical composition containing an antiviral dihydroquinazoline derivative

    JP2015508801A

  • Amorphous letermovir and its solid pharmaceutical formulation for oral administration

    JP2016522238A

  • Pharmaceutical compositions comprising 2-[(4 s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4 h-quinazolin-4-yl]acetate and sodium ions

    WO2021170875A1